Entity

Time filter

Source Type

Kuopio, Finland

Seyedarabi A.,University College London | Cheng L.,Ark Therapeutics Ltd | Cheng L.,University College London | Zachary I.,University College London | Djordjevic S.,University College London
PLoS ONE | Year: 2013

We report a method for production of soluble heparin binding domain (HBD) of human vascular endothelial growth factor VEGF-A165. Recombinant VEGF-A165-HBD that contains four disulphide bridges was expressed in specialised E. coli SHuffle cells and its activity has been confirmed through interactions with neuropilin and heparin. The ability to produce significant quantities of a soluble active form of VEGF-A165-HBD will enable further studies addressing the role of VEGF-A in essential processes such as angiogenesis, vasculogenesis and vascular permeability. © 2013 Seyedarabi et al. Source


Trademark
Ark Therapeutics Ltd | Date: 2010-01-26

Diagnostic protein preparations for use in science, scientific diagnostics and industry; diagnostic preparations of genes for use in science, scientific diagnostics and industry. Pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutics purposes namely for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes namely for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes namely to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes namely for increasing the efficiency of muscle cell energy production. Boots and gloves for orthopaedic and medical purposes; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for socks, boots and gloves for medical purposes, namely, for the treatment of wounds and burns; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; parts and fittings for all the aforesaid goods. Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; advisory services relating to the aforesaid services; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; provision of information relating to the above.


Trademark
Ark Therapeutics Ltd | Date: 2010-11-08

PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC AGENTS FOR TREATING MUSCLE WASTING; PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC AGENTS FOR TREATING CANCER AND MUSCLE WASTING IN CANCER; PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC AGENTS FOR TREATING LIPODYSTROPYY AND OTHER METABOLIC CONDITIONS ASSOCIATED WITH THE USE OF ANTI-HIV THERAPY; PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC AGENTS FOR INCREASING THE EFFICIENCY OF MUSCLE CELL ENERGY PRODUCTION.


Trademark
Ark Therapeutics Ltd | Date: 2012-08-07

Diagnostic protein preparations for use in science, scientific diagnostics, medical laboratory use and research; diagnostic preparations of genes for use in science, scientific diagnostics, medical laboratory use and research. Diagnostic protein preparations for medical use; diagnostic preparations of genes for medical use; pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely, for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutic purposes, namely, for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes, namely, for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes, namely, to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes, namely, for increasing the efficiency of muscle cell energy production; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; none of the above including dietary and nutritional supplements. Boots and gloves for orthopaedic and medical purposes; parts of boots and gloves for orthopedic and medical purposes, namely, heels, soles and inserts; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for boots and gloves for medical purposes, namely, for the treatment of wounds and burns; biodegradable collagen collar delivery devices for delivering therapeutic agents and gene therapy products to specific sites. Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; providing scientific, medical and clinical research information, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; none of the above in the dietary or nutritional supplement field.


Patent
Ark Therapeutics Ltd. | Date: 2012-01-18

An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning the another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.

Discover hidden collaborations